Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sabine Harig"'
Autor:
Svetlana Karakhanova, Beate Mosl, Sabine Harig, Katharina von Ahn, Jasmin Fritz, Jan Schmidt, Dirk Jäger, Jens Werner, Alexandr V. Bazhin
Publikováno v:
International Journal of Molecular Sciences, Vol 15, Iss 3, Pp 4104-4125 (2014)
Prognosis of patients with carcinoma of the exocrine pancreas is particularly poor. A combination of chemotherapy with immunotherapy could be an option for treatment of pancreatic cancer. The aim of this study was to perform an immunomonitoring of 17
Externí odkaz:
https://doaj.org/article/ba2ec9cc6d384a4387e8e77ff13af5ac
Autor:
Dirk Jäger, Ulrich Abel, Christoph Springfeld, Sabine Harig, Christine Komander, Anne Katrin Berger
Publikováno v:
Pancreatology. 14:211-215
Background Pancreatic cancer is mainly a disease of the elderly population, but clinical trials do not reflect this age distribution. Data on treatment strategies and outcome of older patients are limited. The aim of our study was to analyze safety a
Autor:
Beate Mosl, Jasmin Fritz, Jens Werner, Jan Schmidt, Alexandr V. Bazhin, Svetlana Karakhanova, Dirk Jäger, Katharina von Ahn, Sabine Harig
Publikováno v:
International Journal of Molecular Sciences, Vol 15, Iss 3, Pp 4104-4125 (2014)
International Journal of Molecular Sciences; Volume 15; Issue 3; Pages: 4104-4125
International Journal of Molecular Sciences
International Journal of Molecular Sciences; Volume 15; Issue 3; Pages: 4104-4125
International Journal of Molecular Sciences
Prognosis of patients with carcinoma of the exocrine pancreas is particularly poor. A combination of chemotherapy with immunotherapy could be an option for treatment of pancreatic cancer. The aim of this study was to perform an immunomonitoring of 17
Autor:
Ulrich Mansmann, Katrin Hoffmann, Markus W. Büchler, Thomas Herrmann, Ulrich Abel, Detlef K. Bartsch, Sabine Harig, Dirk Jäger, Jan Schmidt, Jürgen Debus, R. Kunz, Justus Klein, Lorenzo Capussotti
Publikováno v:
Journal of Clinical Oncology. 30:4077-4083
Purpose Adjuvant chemotherapy prolongs survival in patients with pancreatic cancer, but its benefit is limited. Long-term survival times of up to 44 months after adjuvant chemoradioimmunotherapy in phase II trials motivated the present study. Patient
Autor:
Ryan J. Broderick, Mathias Witzens, Angela M. Krackhardt, Patrick Barrett, Sabine Harig, John G. Gribben
Publikováno v:
Blood. 100(1)
Chronic lymphocytic leukemia (CLL) cells are ineffective antigen-presenting cells (APCs) although CD40-activated CLL cells can stimulate proliferation of autologous and allogeneic T cells. We examined the antigen-presenting capacity of CD40-activated
Autor:
Andreas Trojan, John W. Donovan, Christina Poor, Sabine Harig, Edie Weller, Robert L. Schlossman, Marco Ladetto, Kenneth C. Anderson, John G. Gribben
The majority of patients with multiple myeloma (MM) have persistence of minimal residual disease (MRD), as determined by polymerase chain reaction (PCR) detection of clonal immunoglobulin H (IgH) gene rearrangements. As a result, PCR analysis has not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f50b54246e84a028b3ae74738c99d52f
http://hdl.handle.net/2318/40678
http://hdl.handle.net/2318/40678
Publikováno v:
The British journal of psychiatry : the journal of mental science. 172
BackgroundIn schizophrenia, disturbances in the development of physiological hemisphere asymmetry are assumed to play a pathogenetic role. The most striking difference between hemispheres is in language processing. The left hemisphere is superior in
Autor:
Angela Märten, Jan Schmidt, M.W. Büchler, J. Klein, Sabine Harig, Lorenzo Capussotti, C. Zülke, K. Lindel, Detlef K. Bartsch, Jürgen Debus
Publikováno v:
Journal of Clinical Oncology. 28:LBA4012-LBA4012
LBA4012 Background:Adjuvant chemomonotherapy in PAC results in five-year survival of 21% with median overall survival (mOS) of 23 months. Phase II trials evaluating adjuvant CRI showed promising results (mOS 27-44 months). Methods: Patients with an R
Autor:
Christiane Decker-Baumann, Sabine Harig, Moritz N. Wente, Ingeborg Rötzer, Irini Karapanagiotou-Schenkel, Markus W. Büchler, Dirk Jäger, Jan Schmidt, Jennifer Ose, Angela Märten
Publikováno v:
BMC Cancer
BMC Cancer, Vol 9, Iss 1, p 412 (2009)
BMC Cancer, Vol 9, Iss 1, p 412 (2009)
Background Pancreatic cancer is an extremely aggressive malignancy. Subjects are afflicted with a variety of disconcerting symptoms, including profound cachexia. Recent data indicate that the outcome of oncological patients suffering from cancer cach
Autor:
Angela Märten, Julia Mayerle, Markus W. Büchler, Marc W. Münter, Guido Adler, Roland M. Schmid, Jennifer Ose, Helmut Friess, Dirk Jäger, Thomas M. Gress, Ulrich Abel, Thomas Seufferlein, Sabine Harig, Jan Schmidt
Publikováno v:
BMC Cancer
BMC Cancer, Vol 9, Iss 1, p 160 (2009)
BMC Cancer, Vol 9, Iss 1, p 160 (2009)
Background The 5-year survival of patients with resected pancreatic adenocarcinoma is still unsatisfying. The ESPAC-1 and the CONKO 001 trial proofed that adjuvant chemotherapy improves 5-year survival significantly from approximately 14% to 21%. In